ANI Pharmaceuticals (ANIP)

[Just the facts maam]

BB, ANIP beat in both revenue and earnings , which is good. However, ANIP is still intentionally lowballing their guidance.

How else can you explain growing Corti guidance to between $80 and $90 million for 2023 and give a revenue guidance of between $360 and $385 million.

$360 million - $275 million (ANIP's non-corti 2022 revenue) = $85 million (mid point of corti estimates for 2023)

It puts out a potential lack in confidence in growing the rest of the business. Which is inconsistent with what they have been saying about Novitium's capabilities to grow revenues and outpace generic price erosion. Or their 10-k filing which shows that they still have a 95% probability of making the Product development-based milestone payments by 2024.
In addition, they expect to complete the Profit-based milestone payments between 2024 and 2029.